Exclusive Summary

• Validated Mechanism & Best-in-Class Efficacy: As an EGFR/cMet bispecific antibody with enhanced ADCC, UB396 demonstrates equivalent preclinical potency to the blockbuster Amivantamab and achieved an outstanding 100% ORR in the front-line combination setting.
• Superior Safety Profile & Tolerability: Characterized by a unique structural design (VHH+Fab) that prevents c-Met auto-activation. Crucially, the clinical safety profile indicates 0% occurrence of Interstitial Lung Disease (ILD), setting it apart from other high-toxicity competitors.
• Clear Freedom to Operate (FTO): The unique molecule sequence ensures no FTO issues globally, presenting a clean, risk-free intellectual property asset for multinational pharmaceutical companies.
• Compelling Lifecycle Management (LCM): Beyond intravenous delivery, bridging studies for a Subcutaneous (SC) formulation have been initiated, promising a significant competitive advantage in patient compliance and healthcare resource utilization.

Asset Materials

Contact Us for Full Materials